Just over a year ago, PDL Pharmaceuticals partnered with MS giant Biogen (Avonex, Tysabri) to bring a drug known as daclizumab through trials for MS. Daclizumab is today used for the prevention of kidney transplant rejection, under the marketing name Zenapax (r). The partnership seems to be bearing fruit, as the companies announced that Daclizumab hit its targets in its first Phase II multiple sclerosis trial.
Please click 'read more'
The rest of this story is hosted at our sister site, Experience Project, run by the same team behind This is MS. It is 100% free, and you may read the rest of the article, vote for it if you like it, and submit your own news postings. Experience Project is about sharing stories and connecting people who have multiple life experiences in common-- like parents who have MS. It creates customized support groups of people who really understand each other. We strongly encourage you to join Experience Project (fast, free and anonymous), share your MS story, and let us know if you you like what you see!
Click to Read: Minimal Changes in Cognitive Function of Relapsing-Remitting MS'ers in a 10-year clinical trial. (link opens in new window)
